

Ref: FOI/GS/ID 7252

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

11 March 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to the incidence and treatment of breast cancer.

You asked:

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- a. Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent*
- b. Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- c. Abemaciclib + Fulvestrant*
- d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent*
- e. Atezolizumab + Nab-paclitaxel/Paclitaxel*
- f. Capecitabine as a single agent*
- g. Carboplatin or Cisplatin as a single agent*
- h. Eribulin as a single agent or in combination*
- i. Everolimus + Exemestane*
- j. Fulvestrant as a single agent*
- k. Lapatinib*
- l. Neratinib*
- m. Parp Inhibitors (Olaparib/Talazoparib)*
- n. Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- o. Palbociclib + Fulvestrant*
- p. Pembrolizumab*
- q. Pertuzumab + Trastuzumab + Docetaxel*
- r. Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- s. Ribociclib + Fulvestrant*
- t. Sacituzumab Govitecan*
- u. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent*

v. *Trastuzumab as a single agent or in combination*

w. *Trastuzumab emtansine*

x. *Transtuzumab deruxtecan*

y. *Vinorelbine as a single agent*

z. *Any other active systemic anti-cancer therapy*

Q2. *In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, letrozole) as a single agent?*

Trust response:

Q1

For the period 1/11/2021-31/1/2022

a. 2

b. 0

c. 3

d. 0

e. 1

f. 13

g. 1

h. 1

i. 3

j. 0

k. 0

l. 0

m. 1

n. 71

o. 23

p. 0

q. 0

r. 4

s. 0

t. 2

u. 9

v. 72

w. 12

x. 0

y. 0

z. 51

Q2. Neither of the patients treated solely with an Aromatase inhibitor has early/locally advanced (Stages I to IIIc) disease.